SCHEMBL25801848

SCHEMBL25801848

C=C(Cc1nc(CCc2ccc(CCC)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ KMT2A Q03164 1/20 0.35
▸ THRB P10828 2/20 0.33
▸ TRPA1 O75762 3/20 0.32
▸ HPGD P15428 3/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ ADRB2 P07550 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ PSMB5 P28074 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23578222 0.93 L3MBTL1 (0.37) L3MBTL1KMT2ATRPA1SMN1; SMN2LMNA
SCHEMBL25801971 0.92 MAPT (0.35) L3MBTL1KMT2AMAPTKDM4EALDH1A1
SCHEMBL23578537 0.90 TRPA1 (0.42) TRPA1LMNAMAPT
SCHEMBL25801788 0.86 ALDH1A1 (0.36) THRBHPGDSMN1; SMN2TP53NPC1
SCHEMBL25801811 0.85 ALDH1A1 (0.37) KMT2ATHRBALDH1A1
SCHEMBL23578446 0.84 TRPA1 (0.37) TRPA1LMNAMAPTALDH1A1
SCHEMBL27022900 0.84 CHRM2 (0.34) KMT2ALMNA
SCHEMBL23588066 0.83 L3MBTL1 (0.44) L3MBTL1KMT2ATHRBTRPA1HPGD
SCHEMBL23578531 0.83 CHRM2 (0.35) KMT2ALMNA
SCHEMBL23578580 0.83 CHRM2 (0.35) KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4442319-A2 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2024-10-09 — — EP disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 — — EP disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 L3MBTL1 3425/4885KMT2A 3125/4885THRB 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback